Clinical Trial Update: MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) [Phase 1]

View source ↗

Summary

This Phase 1 trial (MK-4827-011) evaluated niraparib in combination with pegylated liposomal doxorubicin in participants with advanced solid tumors and ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Ovarian Cancer | Phase 1 | Status: TERMINATED